10-Q/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q/A

Amendment No. 1

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended June 30, 2012

OR

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934
	For the transition period from  ____________ to ____________

Commission File Number: 1-12584

SYNTHETIC BIOLOGICS, INC.

(Name of small business issuer in its charter)

Nevada	13-3808303
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification Number)
617 Detroit Street, Suite 100
Ann Arbor, MI	48104
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:

(734) 332-7800

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.001 par value per share

Securities registered pursuant to Section 12(g) of the Act:

None.

(Title of Class)

Indicate by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes   x        No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes   x       No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated file, a non-accelerated file, or a smaller reporting company.  See the definitions of “large accelerated filer, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

Large accelerated filer                                 ¨	Accelerated filer                                 ¨
Non-Accelerated filer                                  ¨	Smaller reporting company               x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ¨       No  x

As of August 9, 2012, the registrant had 33,395,538 shares of common stock outstanding.

Explanatory Note

Synthetic Biologics, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (the “Amendment”) to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2012 (the “Form 10-Q”), filed with the Securities and Exchange Commission on August 14, 2012 (the “Original Filing Date”), for the sole purpose of furnishing Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 consists of the following materials from the Form 10-Q, formatted in XBRL (eXtensible Business Reporting Language):

101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Schema
101.CAL	XBRL Taxonomy Calculation Linkbase
101.DEF	XBRL Taxonomy Definition Linkbase
101.LAB	XBRL Taxonomy Label Linkbase
101.PRE	XBRL Taxonomy Presentation Linkbase

No other changes have been made to the Form 10-Q. This Amendment speaks as of the Original Filing Date, does not reflect events that may have occurred subsequent to the Original Filing Date, and does not modify or update in any way disclosures made in the Form 10-Q.

Pursuant to Rule 406T of Regulation S-T, the interactive data files attached as Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.                         

Item 6.  Exhibits

Exhibit Number	Exhibit Title
31.1*	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS **	XBRL Instance Document
101.SCH **	XBRL Taxonomy Schema
101.CAL **	XBRL Taxonomy Calculation Linkbase
101.DEF **	XBRL Taxonomy Definition Linkbase
101.LAB **	XBRL Taxonomy Label Linkbase
101.PRE **	XBRL Taxonomy Presentation Linkbase

* Previously filed as an exhibit to the Company’s Form 10-Q for the period ended June 30, 2012 filed with the Securities and Exchange Commission on August 14, 2012.

** Furnished herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

SYNTHETIC BIOLOGICS, INC.
By:	/s/ Jeffrey Riley
	Jeffrey Riley
	President and Chief Executive Officer
	(Principal Executive Officer)
	Date: September 11, 2012

By:	/s/ C. Evan Ballantyne
	C. Evan Ballantyne
	Chief Financial Officer
	(Principal Financial Officer)
	Date: September 11, 2012

XML

Subsequent Event (Details Textual)	Aug. 06, 2012
Common Stock Agreed To Be Issued During Period	3,552,210
Percentage Of Number Of Shares Outstanding Prior To Issuance Of Shares (Issued and to be Issued to Intrexon Corporation)	19.99%

XML

Stock-Based Compensation (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Expected dividends	0.00%	0.00%	0.00%	0.00%
Expected volatility	171.00%	184.00%
Risk free interest rates		2.88%
Expected life options		7 years
Expected forfeitures	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Exercise price	1.70	1.21	1.70	1.21
Expected volatility			108.00%	184.00%
Risk free interest rates	1.89%		0.37%	2.81%
Expected life options	7 years		7 years	5 years
Maximum [Member]
Exercise price	2.47	2.22	2.47	2.22
Expected volatility			174.00%	188.00%
Risk free interest rates	1.92%		1.98%	3.58%
Expected life options	10 years		10 years	7 years

XML

Selected Balance Sheet Information

6 Months Ended

Jun. 30, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Supplemental Balance Sheet Disclosures [Text Block]

4.   Selected Balance Sheet Information

Accounts receivable consisted of the following at June 30, 2012 and December 31, 2011 (in thousands):

	June 30, 2012			December 31, 2011
Accounts receivable	$	699		$	692
Bad debt allowance - customer		(454	)		(287	)
Accounts receivable, net	$	245		$	405

Property and Equipment consisted of the following at June 30, 2012, and December 31, 2011 (in thousands) :

	June 30, 2012			December 31, 2011
Manufacturing equipment	$	335		$	400
Computer and office equipment		25			159
Laboratory equipment		133			136
Total		493			695
Less accumulated depreciation		(239	)		(372	)
Property and equipment, net	$	254		$	323

Depreciation expense for the six months ended June 30, 2012 and 2011 was approximately $39,000 and $101,000, respectively.

XML

Stock Purchase Warrants (Details 1) (Warrant [Member], USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2012	Dec. 31, 2011
Warrant [Member]
Balance, Warrants	3,259,186	1,131,078
Granted, Warrants	350,000	2,272,963
Exercised, Warrants	(1,673,776)	(15,615)
Expired, Warrants	(516,917)	(129,240)
Balance, Warrants	1,418,493	3,259,186
Balance - Weighted Average Exercise Price	$ 1.99	$ 3.49
Granted, Weighted Average Exercise Price	$ 1.90	$ 1.25
Exercised, Weighted Average Exercise Price	$ 1.11	$ 1.03
Expired, Weighted Average Exercise Price	$ 1.40	$ 2.08
Balance - Weighted Average Exercise Price	$ 3.10	$ 1.99
Balance - Exercisable	1,218,493
Balance - Exercisable, Weighted Average Exercise Price	$ 3.25

XML

Stock Purchase Warrants (Details) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Consulting Agreement For Financial Communications Program [Member]	Dec. 31, 2011 Consulting Agreement For Financial Advisory Services [Member]
Exercise price					$ 2.20	$ 1.14
Expected dividends	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Expected volatility	171.00%	184.00%			108.00%	174.00%
Risk free interest rate		2.88%			0.37%	0.71%
Expected life of warrant		7 years			2 years	5 years
Expected forfeitures	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

XML

Stock Purchase Warrants (Details 2) (USD $)	6 Months Ended
	Jun. 30, 2012
Warrants Outstanding	1,418,493
Warrants Exercisable	1,218,493
Weighted Average Remaining Contractual Life	1 year 9 months 22 days
Aggregate Intrinsic value	$ 189,000
Warrant [Member] | Exercise Price 1.00 [Member]
Exercise Price	$ 1.00
Warrants Outstanding	94,391
Warrants Exercisable	94,391
Weighted Average Remaining Contractual Life	0 years 1 month 10 days
Aggregate Intrinsic value	$ 93,000
Warrant [Member] | Exercise Price 1.14 [Member]
Exercise Price	$ 1.14
Warrants Outstanding	100,000
Warrants Exercisable	100,000
Weighted Average Remaining Contractual Life	4 years 7 months 3 days
Aggregate Intrinsic value	$ 84,000
Warrant [Member] | Exercise Price 1.32 [Member]
Exercise Price	$ 1.32
Warrants Outstanding	18,182
Warrants Exercisable	18,182
Weighted Average Remaining Contractual Life	3 years 6 months
Aggregate Intrinsic value	$ 12,000
Warrant [Member] | Exercise Price 2.20 [Member]
Exercise Price	$ 2.20
Warrants Outstanding	250,000
Warrants Exercisable	50,000
Weighted Average Remaining Contractual Life	1 year 8 months 16 days
Aggregate Intrinsic value	$ 0
Warrant [Member] | Exercise Price 2.22 [Member]
Exercise Price	$ 2.22
Warrants Outstanding	517,257
Warrants Exercisable	517,257
Weighted Average Remaining Contractual Life	4 years 4 months 28 days
Aggregate Intrinsic value	$ 0
Warrant [Member] | Exercise Price 3.30 [Member]
Exercise Price	$ 3.30
Warrants Outstanding	61,207
Warrants Exercisable	61,207
Weighted Average Remaining Contractual Life	3 years 11 months 1 day
Aggregate Intrinsic value	$ 0
Warrant [Member] | Exercise Price 3.75 [Member]
Exercise Price	$ 3.75
Warrants Outstanding	50,000
Warrants Exercisable	50,000
Weighted Average Remaining Contractual Life	3 years 7 months 17 days
Aggregate Intrinsic value	$ 0
Warrant [Member] | Exercise Price 6.36 [Member]
Exercise Price	$ 6.36
Warrants Outstanding	327,456
Warrants Exercisable	327,456
Weighted Average Remaining Contractual Life	0 years 4 months 10 days
Aggregate Intrinsic value	$ 0

XML

Stock Purchase Warrants (Details Textual) (USD $)	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended			6 Months Ended		6 Months Ended			3 Months Ended	12 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Warrant [Member]	Jun. 30, 2011 Warrant [Member]	Jun. 30, 2012 Warrant [Member]	Jun. 30, 2011 Warrant [Member]	Feb. 20, 2012 Consulting Agreement For Financial Communications Program [Member]	Jun. 30, 2012 Consulting Agreement For Financial Communications Program [Member] Warrant [Member]	Dec. 20, 2011 Consulting Agreement For Financial Advisory Services [Member]	Dec. 31, 2011 Consulting Agreement For Financial Advisory Services [Member] Warrant [Member]	Dec. 31, 2011 Common Stock Purchase Agreement With Institutional Investors [Member]	Jun. 30, 2012 Common Stock Purchase Agreement With Institutional Investors [Member]	Mar. 31, 2011 Stock Purchase Agreement With Three Institutional Investors [Member]	Dec. 31, 2010 Stock Purchase Agreement With Single Investor [Member]	Jun. 30, 2012 Stock Purchase Agreement With Single Investor [Member]
Warrants Exercisable For Compensation									250,000		100,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period										50,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Total Fair Value										$ 61,000		$ 200,000
Warrants Exercise Price Per Share													$ 1.00		$ 1.40	$ 1.32
Issuance Of Warrants To Purchase Of Common Stock													844,391		1,428,572	60,606
Warrants Expiration Date															Aug. 10, 2012	Dec. 31, 2015
Class Of Warrant Or Right, Outstanding														94,391			18,182
Allocated Share-based Compensation Expense	$ 400,000	$ 57,000	$ 908,000	$ 427,000	$ 0	$ 760,000	$ 270,000	$ 1,600,000

XML

Discontinued Operations of Adeona Clinical Laboratory and Note Receivable

6 Months Ended

Jun. 30, 2012

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

3. Discontinued Operations of Adeona Clinical Laboratory and Note Receivable

On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the “Lab”) to Hartlab, LLC, an entity controlled by the Lab’s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab’s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid interest are due on March 1, 2014.

In accordance with ASC Topic 205-20 “ Presentation of Financial Statements—Discontinued Operations ” (ASC 205-20), the Company determined that all the criteria had been met and classified the Lab as discontinued operations and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets of the discontinued operations are presented separately under the caption “Assets of discontinued operations” in the accompanying Consolidated Balance Sheets at June 30, 2012, and December 31, 2011, and consist of the following (in thousands):

	June 30, 2012		December 31, 2011
Assets of discontinued operations:
Property and equipment, net	$	-	$	23
Total assets	$	-	$	23

The summarized statement of operations data for Adeona Clinical Laboratory for the three and six months ended June 30, 2012 and June 30, 2011 are as follows (in thousands):

	Three months ended June 30,						Six months ended June 30,
	2012			2011			2012			2011
Laboratory fees, net	$	-		$	356		$	115		$	679
Operating Costs and Expenses:
General and administrative		156			169			183			211
Cost of laboratory services		-			301			116			545
Total operating costs and expenses		156			470			299			756
Loss from discontinued operations		(156	)		(114	)		(184	)		(77	)
Other Income:
Gain on sale of Adeona Clinical Laboratory		-			-			677			-
Income (loss) from discontinued operations	$	(156	)	$	(114	)	$	493		$	(77	)

XML

Stockholders' Equity (Details Textual) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Options Exercised	334,851	10,000	23,333
Stock Issued During Period, Value, Stock Options Exercised	$ 88,000
Stock Issued During Period Shares Stock Warrants Exercised	1,673,776
Proceeds From Issuance Of Warrants	$ 1,900,000

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
Assets
Cash	$ 5,932	$ 6,678
Accounts receivable - net	245	405
Other	94	16
Assets of discontinued operations	0	23
Total Current Assets	6,271	7,122
Property and equipment, net	254	323
Long-term note receivable	700	0
Deposits and other assets	20	31
Total Assets	7,245	7,476
Liabilities and Stockholders' Equity
Accounts payable	278	388
Accrued liabilities	117	29
Total Current Liabilities	395	417
Total Liabilities	395	417
Commitments and Contingencies
Stockholders' Equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 33,382,629 issued and 33,301,147 outstanding as of June 30, 2012 and 31,374,002 issued and 31,292,520 outstanding as of December 31, 2011	33	31
Additional paid-in capital	61,762	58,901
Accumulated deficit	(54,945)	(51,873)
Total Stockholders' Equity	6,850	7,059
Total Liabilities and Stockholders' Equity	$ 7,245	$ 7,476

XML

Organization

6 Months Ended

Jun. 30, 2012

Accounting Policies [Abstract]

Nature of Operations [Text Block]

1.   Organization

Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic biologics and innovative medicines to address serious diseases and unmet medical needs. The Company is developing the following synthetic biologic candidates: a series of monoclonal antibodies (mAbs) for the treatment of infectious diseases not adequately addressed by existing therapies and a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension (PAH). The Company also intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, amyotrophic lateral sclerosis (ALS) and fibromyalgia.

Medical Indication	Product Candidate	Status
Infectious disease	SYN-ID-001	Discovery; Collaboration with Intrexon
	(Monoclonal antibody)
Infectious disease	SYN-ID-002	Discovery; Collaboration with Intrexon
	(Monoclonal antibody)
Infectious disease	SYN-ID-003	Discovery; Collaboration with Intrexon
	(Monoclonal antibody)
PAH	SYN-PAH-001	Preclinical; Collaboration with Intrexon
	(Synthetic DNA-based therapy)
Relapsing-remitting MS	Trimesta (oral estriol)	All patients enrolled in Phase II clinical trial; dosing and monitoring underway
Cognitive dysfunction in MS	Trimesta (oral estriol)	Patient enrollment underway in Phase II clinical trial
ALS	AEN-100	Phase II/III clinical trial preparation underway
	(gastroretentive zinc acetate)
Fibromyalgia	Effirma	Partnered with Meda AB
	(oral flupirtine)

XML

Selected Balance Sheet Information (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
Accounts receivable	$ 699	$ 692
Bad debt allowance - customer	(454)	(287)
Accounts receivable - net	$ 245	$ 405

XML

Selected Balance Sheet Information (Details Textual) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Depreciation	$ 39	$ 101

XML

Basis of Presentation

6 Months Ended

Jun. 30, 2012

Accounting Policies [Abstract]

Business Description and Basis of Presentation [Text Block]

2.   Basis of Presentation

The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly they do not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state our results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K/A for the year ended December 31, 2011 (“2011 Form 10-K”) as filed with the SEC. The interim results for the three and six month periods ended June 30, 2012, are not necessarily indicative of results for the full year.

The consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

XML

Consolidated Balance Sheets [Parenthetical] (USD $)	Jun. 30, 2012	Dec. 31, 2011
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	33,382,629	31,374,002
Common stock, shares outstanding	33,301,147	31,292,520

XML

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Share Based Compensation Arrangement By Share Based Payment Award Options And Warrants Vested And Expected To Vest Outstanding And Exercisable [Table Text Block]

The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the months ended June 30, 2012 and 2011 are as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
Exercise price		$1.70 - $1.75		$1.73		$1.70 – $2.47		$1.21 – $2.22
Expected dividends		0%		0%		0%		0%
Expected volatility		171%		184%		108% – 174%		184% – 188%
Risk free interest rates		1.89% – 1.92%		2.88%		0.37% – 1.98%		2.81% – 3.58%
Expected life options		10 years		7 years		10 years		5 years – 7 years
Expected forfeitures		0%		0%		0%		0%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of stock option activities as of June 30, 2012, and for the year ended December 31, 2011, is as follows:

	Options			Weighted Average  Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
Balance – December 31, 2010		2,539,091		$	1.32
Granted		557,002			1.26
Exercised		(23,333	)		0.57
Forfeited or expired		(93,750	)		0.59
Balance – December 31, 2011		2,979,010			1.34
Granted		1,550,000			2.25
Exercised		(334,851	)		0.28
Forfeited or expired		(225,413	)		2.37
Balance – June 30, 2012 – outstanding		3,968,746		$	1.73		7.17 years	$	1,547,000
Balance – June 30, 2012 – exercisable		2,412,748		$	1.54		5.93 years	$	1,252,000

XML

Document and Entity Information	6 Months Ended
	Jun. 30, 2012	Aug. 09, 2012
Entity Registrant Name	Synthetic Biologics, Inc.
Entity Central Index Key	0000894158
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	syn
Entity Common Stock, Shares Outstanding		33,395,538
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2012
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2012

XML

Stock Purchase Warrants (Tables)

6 Months Ended

Jun. 30, 2012

Stock Purchase Warrants [Abstract]

Schedule Of Share Based Payment Fair Value Assumptions Fair Value Measurement Of Warrants [Table Text Block]

The assumptions used by the Company are summarized in the following table:

Exercise price	$	2.20
Expected dividends		0	%
Expected volatility		108	%
Risk free interest rate		0.37	%
Expected life of warrant		2 years
Expected forfeitures		0	%

 The assumptions used by the Company are summarized in the following table:

Exercise price	$	1.14
Expected dividends		0	%
Expected volatility		174	%
Risk free interest rate		0.71	%
Expected life of warrant		5 years
Expected forfeitures		0	%

Schedule of Other Share-based Compensation, Activity [Table Text Block]

A summary of warrant activities as of June 30, 2012, and for the year ended December 31, 2011, is as follows:

	Warrants			Weighted Average Exercise Price
Balance – December 31, 2010		1,131,078		$	3.49
Granted		2,272,963			1.25
Exercised		(15,615	)		1.03
Expired		(129,240	)		2.08
Balance – December 31, 2011		3,259,186			1.99
Granted		350,000			1.90
Exercised		(1,673,776	)		1.11
Cancelled by cashless exercise		(516,917	)		1.40
Balance – June 30, 2012 – outstanding		1,418,493		$	3.10
Balance – June 30, 2012 – exercisable		1,218,493		$	3.25

Schedule Of Other Share Based Compensation Warrants Outstanding [Table Text Block]

The warrants outstanding as of June 30, 2012, are as follows:

Exercise Price		Warrants Outstanding		Warrants Exercisable		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
$	1.00		94,391		94,391		0.11 years	$	93,000
$	1.14		100,000		100,000		4.59 years		84,000
$	1.32		18,182		18,182		3.50 years		12,000
$	2.20		250,000		50,000		1.71 years		-
$	2.22		517,257		517,257		4.41 years		-
$	3.30		61,207		61,207		3.92 years		-
$	3.75		50,000		50,000		3.63 years		-
$	6.36		327,456		327,456		0.36 years		-
			1,418,493		1,218,493		1.81 years	$	189,000

XML

Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Operating Costs and Expenses:
General and administrative	$ 1,176	$ 524	$ 2,644	$ 1,757
Research and development	547	281	933	512
Total Operating Costs and Expenses	1,723	805	3,577	2,269
Loss from Continuing Operations	(1,723)	(805)	(3,577)	(2,269)
Other Income (Expense):
Warrant expense	0	(776)	0	(1,492)
Change in fair value of warrant liability	0	16	0	(78)
Other income (expense)	7	(1)	12	50
Total Other Income (Expense), net	7	(761)	12	(1,520)
Loss from Continuing Operations	(1,716)	(1,566)	(3,565)	(3,789)
Income (Loss) from Discontinued Operations	(156)	(114)	493	(77)
Net Loss and Comprehensive Loss	$ (1,872)	$ (1,680)	$ (3,072)	$ (3,866)
Net Income (Loss) Per Share - Basic and Dilutive:
Continuing operations (in dollars per share)	$ (0.05)	$ (0.06)	$ (0.11)	$ (0.14)
Discontinued operations (in dollars per share)	$ 0	$ 0	$ 0.02	$ 0
Net Loss Per Share (in dollars per share)	$ (0.05)	$ (0.06)	$ (0.09)	$ (0.14)
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)	33,011,460	27,885,479	32,507,312	26,560,448

XML

Stockholders' Equity

6 Months Ended

Jun. 30, 2012

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

7.   Stockholders’ Equity

During the six months ended June 30, 2012, the Company issued 334,851 shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $88,000. The Company also issued 1,673,776 shares of common stock in connection with the exercise of warrants, for proceeds of approximately $1.9 million.

XML

Stock Purchase Warrants

6 Months Ended

Jun. 30, 2012

Stock Purchase Warrants [Abstract]

Stock Purchase Warrants [Text Block]

6.   Stock Purchase Warrants

On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for 250,000 shares of the Company’s common stock based on achievement of certain milestones. Upon initiation of the program, 50,000 of the performance warrants will vest. The performance warrant is exercisable for a period of two years from the date the agreement was executed for an exercise price equal to the price of the Company’s common stock on the date of execution. Approval of these warrants from NYSE MKT is pending. The expense recorded for the six months ended June 30, 2012 approximated $61,000 and was estimated using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:

Exercise price	$	2.20
Expected dividends		0	%
Expected volatility		108	%
Risk free interest rate		0.37	%
Expected life of warrant		2 years
Expected forfeitures		0	%

On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company’s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company’s common stock on the date of issue. The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:

Exercise price	$	1.14
Expected dividends		0	%
Expected volatility		174	%
Risk free interest rate		0.71	%
Expected life of warrant		5 years
Expected forfeitures		0	%

On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrants have an exercise price of $1.00 and a life of fifteen months. The warrants vested immediately and expire August 10, 2012. As of June 30, 2012, 94,391 of these warrants remained outstanding.

On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. The warrants have an exercise price of $1.40 and a life of fifteen months. The warrants vested immediately and all warrants were exercised.

On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of June 30, 2012, there were 18,182 warrants outstanding.

A summary of warrant activities as of June 30, 2012, and for the year ended December 31, 2011, is as follows:

	Warrants			Weighted Average Exercise Price
Balance – December 31, 2010		1,131,078		$	3.49
Granted		2,272,963			1.25
Exercised		(15,615	)		1.03
Expired		(129,240	)		2.08
Balance – December 31, 2011		3,259,186			1.99
Granted		350,000			1.90
Exercised		(1,673,776	)		1.11
Cancelled by cashless exercise		(516,917	)		1.40
Balance – June 30, 2012 – outstanding		1,418,493		$	3.10
Balance – June 30, 2012 – exercisable		1,218,493		$	3.25

The Company recognized $0 and $760,000 in compensation expense relating to stock purchase warrants for the three month periods ended June 30, 2012 and 2011, respectively, and $270,000 and $1.6 million for the six month periods ended June 30, 2012 and 2011.

 The warrants outstanding as of June 30, 2012, are as follows:

Exercise Price		Warrants Outstanding		Warrants Exercisable		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
$	1.00		94,391		94,391		0.11 years	$	93,000
$	1.14		100,000		100,000		4.59 years		84,000
$	1.32		18,182		18,182		3.50 years		12,000
$	2.20		250,000		50,000		1.71 years		-
$	2.22		517,257		517,257		4.41 years		-
$	3.30		61,207		61,207		3.92 years		-
$	3.75		50,000		50,000		3.63 years		-
$	6.36		327,456		327,456		0.36 years		-
			1,418,493		1,218,493		1.81 years	$	189,000

XML

Selected Balance Sheet Information (Details 1) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
Property, Plant and Equipment, Gross	$ 493	$ 695
Less accumulated depreciation	(239)	(372)
Property and equipment, net	254	323
Manufacturing equipment [Member]
Property, Plant and Equipment, Gross	335	400
Computer and Office Equipment [Member]
Property, Plant and Equipment, Gross	25	159
Laboratory Equipment [Member]
Property, Plant and Equipment, Gross	$ 133	$ 136

XML

Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
Assets of discontinued operations:
Property and equipment, net	$ 0	$ 23
Total assets	$ 0	$ 23

XML

Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)

6 Months Ended

Jun. 30, 2012

Discontinued Operations and Disposal Groups [Abstract]

Schedule Of Disposal Groups Including Discontinued Operations Balance Sheet and Additional Disclosures [Table Text Block]

The assets of the discontinued operations are presented separately under the caption “Assets of discontinued operations” in the accompanying Consolidated Balance Sheets at June 30, 2012, and December 31, 2011, and consist of the following (in thousands ):

	June 30, 2012		December 31, 2011
Assets of discontinued operations:
Property and equipment, net	$	-	$	23
Total assets	$	-	$	23

Schedule Of Disposal Groups Including Discontinued Operations Income Statement and Additional Disclosures [Table Text Block]

The summarized statement of operations data for Adeona Clinical Laboratory for the three and six months ended June 30, 2012 and June 30, 2011 are as follows (in thousands):

	Three months ended June 30,						Six months ended June 30,
	2012			2011			2012			2011
Laboratory fees, net	$	-		$	356		$	115		$	679
Operating Costs and Expenses:
General and administrative		156			169			183			211
Cost of laboratory services		-			301			116			545
Total operating costs and expenses		156			470			299			756
Loss from discontinued operations		(156	)		(114	)		(184	)		(77	)
Other Income:
Gain on sale of Adeona Clinical Laboratory		-			-			677			-
Income (loss) from discontinued operations	$	(156	)	$	(114	)	$	493		$	(77	)

XML

Subsequent Event

6 Months Ended

Jun. 30, 2012

Subsequent Events [Abstract]

Subsequent Events [Text Block]

8.   Subsequent Event

Upon recommendation of the Audit Committee and unanimous approval by the Company’s Board of Directors, on July 3, 2012, the Company dismissed Berman & Company, P.A. as its independent registered public accounting firm. In July 2012, the Company retained BDO USA, LLP as its new independent registered public accounting firm responsible for auditing its financial statements.  

On August 6, 2012, Synthetic Biologics, Inc. expanded its relationship with Intrexon Corporation (“Intrexon”) and entered into an Exclusive Channel Collaboration Agreement (the “Channel Agreement”) with Intrexon that governs a “channel collaboration” arrangement in which the Company will use Intrexon’s technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases (collectively, the “Program”). The Channel Agreement establishes committees comprised of Company and Intrexon representatives that will govern activities related to the Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property.

The Company also entered into a Stock Issuance Agreement with Intrexon pursuant to which the Company has agreed to issue to Intrexon 3,552,210 shares of the Company’s common stock, which is equal to the difference between (i) 19.99% of the number of shares of Common Stock of Company outstanding as of the date of the closing prior to the issuance of such shares, and (ii) the number of shares of Common Stock of Company held by Intrexon immediately prior to the Closing (the “Technology Access Shares”), which issuance will be deemed paid in partial consideration for the execution and delivery of the Channel Agreement.

XML

Recent Accounting Pronouncements

6 Months Ended

Jun. 30, 2012

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

9.   Recent Accounting Pronouncements

There were no accounting standards or interpretations issued or recently adopted that are expected to have a material impact on the Company’s financial position, operations, or cash flows.

XML

Selected Balance Sheet Information (Tables)

6 Months Ended

Jun. 30, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

Accounts receivable consisted of the following at June 30, 2012 and December 31, 2011 (in thousands):

	June 30, 2012			December 31, 2011
Accounts receivable	$	699		$	692
Bad debt allowance - customer		(454	)		(287	)
Accounts receivable, net	$	245		$	405

Property, Plant and Equipment [Table Text Block]

Property and Equipment consisted of the following at June 30, 2012, and December 31, 2011 (in thousands) :

	June 30, 2012			December 31, 2011
Manufacturing equipment	$	335		$	400
Computer and office equipment		25			159
Laboratory equipment		133			136
Total		493			695
Less accumulated depreciation		(239	)		(372	)
Property and equipment, net	$	254		$	323

XML

Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual) (Promissory Note [Member], Adeona Clinical Laboratory, Llc [Member], USD $)	6 Months Ended
	Jun. 30, 2012
Promissory Note [Member] | Adeona Clinical Laboratory, Llc [Member]
Notes Payable	$ 700,000
Line Of Credit Facility, Frequency Of Payments	the terms of a two-year
Line Of Credit Facility, Interest Rate At Period End	5.70%
Debt Instrument, Maturity Date	Mar. 01, 2014

XML

Stock-Based Compensation (Details 1) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Options Balance	2,979,010	2,539,091	2,539,091
Weighted Average Exercise Price Outstanding	$ 1.34	$ 1.32	$ 1.32
Options Granted	1,550,000		557,002
Weighted Average Exercise Price Granted	$ 2.25	$ 1.34	$ 1.26
Options Exercised	(334,851)	(10,000)	(23,333)
Weighted Average Exercise Price Excercised	$ 0.28		$ 0.57
Options Forfeited or expired	(225,413)		(93,750)
Weighted Average Exercise Price Forfeited or expired	$ 2.37		$ 0.59
Options Balance	3,968,746		2,979,010
Weighted Average Exercise Price Outstanding	$ 1.73		$ 1.34
Weighted Average Remaining Contractual Life, Options Outstanding	7 years 2 months 1 day
Aggregate Intrinsic Value Balance outstanding	$ 1,547,000
Balance exercisable Options	2,412,748
Balance exercisable, Weighted Average Exercise Price	$ 1.54
Weighted Average Remaining Contractual Life Balance exercisable	5 years 11 months 4 days
Balance excercisable Aggregate Intrinsic Value	$ 1,252,000

XML

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash Flows From Operating Activities:
Net loss	$ (3,072)	$ (3,866)
Adjustments to reconcile net loss to net cash used in operating activites:
Stock-based compensation	908	427
Stock option modification expense	0	398
Stock issued as employee compensation	0	76
Stock issued for consulting fees	0	58
Warrant expense	0	1,492
Change in fair value of warrant liability	0	78
Depreciation	39	101
Provision for uncollectible accounts receivable	165	188
Gain on the sale of discontinued operations	(677)	0
Gain on sale of equipment	0	6
Impairment on loss of equipment	30	0
Gain on the settlement of accounts payable	0	(63)
Changes in operating assets and liabilities:
Accounts receivable	(5)	(295)
Other current assets	(78)	268
Deposits and other assets	11	50
Assets of discontinued operations	0	6
Accounts payable	(110)	54
Accrued liabilities	88	(187)
Liabilities of discontinued operations	0	(24)
Net Cash Used In Operating Activities	(2,701)	(1,233)
Cash Flows From Investing Activities:
Proceeds from the sale of equipment	0	1
Net Cash Provided By Investing Activities	0	1
Cash Flows From Financing Activities:
Proceeds from issuance of common stock for stock option exercises	94	8
Proceeds from issuance of common stock for warrant exercises	1,861	0
Proceeds from issuance of common stock, net offering costs $296	0	6,961
Net Cash Provided By Financing Activities	1,955	6,969
Net increase (decrease) in cash	(746)	5,737
Cash at beginning of period	6,678	2,649
Cash at end of period	5,932	8,386
Supplemental disclosures of cash flow information:
Cash paid for interest	0	0
Cash paid for taxes	$ 0	$ 0

XML

Stock-Based Compensation

6 Months Ended

Jun. 30, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

5.   Stock-Based Compensation

During 2001, Pipex Therapeutics’ Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the “2001 Stock Plan”). This plan was assumed by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee’s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the “Awards”). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of June 30, 2012, there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.

On March 20, 2007, the Company’s Board of Directors approved the Company’s 2007 Stock Incentive Plan (the “2007 Stock Plan”) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of June 30, 2012, there are 912,739 options issued and outstanding under the 2007 Stock Plan.

On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (“2010 Stock Plan”) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire seven to ten years after the grant date. As of June 30, 2012, there are 1,990,000 options issued and outstanding under the 2010 Stock Plan.

In the event of an employee’s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.

The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the months ended June 30, 2012 and 2011 are as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2012		2011		2012		2011
Exercise price		$1.70 - $1.75		$1.73		$1.70 – $2.47		$1.21 – $2.22
Expected dividends		0%		0%		0%		0%
Expected volatility		171%		184%		108% – 174%		184% – 188%
Risk free interest rates		1.89% – 1.92%		2.88%		0.37% – 1.98%		2.81% – 3.58%
Expected life options		7 years – 10 years		7 years		7 years – 10 years		5 years – 7 years
Expected forfeitures		0%		0%		0%		0%

The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:

● immediate vesting,

● one-half vesting immediately and the remainder over three years

● monthly over three years,

● quarterly over three years,

● annually over three years,

● one-third immediate vesting and remaining annually over two years,

● one-eighth immediate vesting with remaining vesting over two years,

● one-half immediate vesting with remaining vesting over nine months; and

● one quarter immediate vesting with the remaining over three years.

During the six months ended June 30, 2012, the Company granted 1,550,000 options to employees and consultants having a fair value of approximately $3.5 million based upon the Black-Scholes option pricing model.  During the same period of 2011, the Company granted 332,002 options to employees having a fair value of approximately $446,000 based upon the Black-Scholes option pricing model.

A summary of stock option activities as of June 30, 2012, and for the year ended December 31, 2011, is as follows:

	Options			Weighted Average  Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
Balance – December 31, 2010		2,539,091		$	1.32
Granted		557,002			1.26
Exercised		(23,333	)		0.57
Forfeited or expired		(93,750	)		0.59
Balance – December 31, 2011		2,979,010			1.34
Granted		1,550,000			2.25
Exercised		(334,851	)		0.28
Forfeited or expired		(225,413	)		2.37
Balance – June 30, 2012 – outstanding		3,968,746		$	1.73		7.17 years	$	1,547,000
Balance – June 30, 2012 – exercisable		2,412,748		$	1.54		5.93 years	$	1,252,000

The weighted-average grant-date fair value of options granted during the six month period ended June 30, 2012 and 2011 was $2.24 and $1.34, respectively.

During the six month period ended June 30, 2012 and 2011, 334,851 and 10,000 stock options were exercised, respectively.

The Company recognized $400,000 and $57,000 in stock-based compensation expense relating to stock options during the three month periods ended June 30, 2012 and 2011, respectively, and $908,000 and $427,000 during the six month periods ended June 30, 2012 and 2011, respectively.

As of June 30, 2012, total unrecognized stock-based compensation expense related to stock options was $3.1 million, which is expected to be expensed through May 2015.

XML

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended		6 Months Ended				12 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Jun. 30, 2012 Employees and Consultants [Member]	Jun. 30, 2011 Employees and Consultants [Member]	Jun. 30, 2012 2001 Stock Plan [Member]	Oct. 31, 2006 2001 Stock Plan [Member]	Dec. 31, 2006 2001 Stock Plan [Member] Stock Options and Stock Appreciation Rights Sars [Member]	Jun. 30, 2012 2007 Stock Plan [Member]	Mar. 20, 2007 2007 Stock Plan [Member]	Jun. 30, 2012 2010 Stock Plan [Member]	Nov. 02, 2010 2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,968,746		3,968,746		2,979,010	2,539,091	0		1,066,007	1,489,353		912,739	2,500,000	1,990,000	3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							1,550,000	332,002			250,000
Stock Granted During Period, Value, Share-based Compensation, Gross							$ 3,500,000	$ 446,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value			$ 2.25	$ 1.34	$ 1.26
Options Exercised			334,851	10,000	23,333
Allocated Share-based Compensation Expense	400,000	57,000	908,000	427,000
Expected Unrecognised Share Based Compensation Cost	$ 3,100,000		$ 3,100,000

XML

Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details 1) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Operating Costs and Expenses:
General and administrative	$ 1,176	$ 524	$ 2,644	$ 1,757
Total operating costs and expenses	1,723	805	3,577	2,269
Other Income:
Gain on sale of Adeona Clinical Laboratory			677	0
Income (loss) from discontinued operations	(156)	(114)	493	(77)
Adeona Clinical Laboratory [Member]
Laboratory fees, net	0	356	115	679
Operating Costs and Expenses:
General and administrative	156	169	183	211
Cost of laboratory services	0	301	116	545
Total operating costs and expenses	156	470	299	756
Loss from discontinued operations	(156)	(114)	(184)	(77)
Other Income:
Gain on sale of Adeona Clinical Laboratory	$ 0	$ 0	$ 677	$ 0